Does Hormone-Modulating Therapy for Breast Cancer Affect Risk for Neurodegenerative Disease?

Surprisingly, tamoxifen and aromatase inhibitors were associated with lower incidence of neurodegenerative outcomes.

After initial treatment, women with hormone-receptor–positive breast cancers usually receive hormone-modulating therapy (HMT), either tamoxifen or an aromatase inhibitor (AI), often for 5 to 10 years. In this retrospective cohort study, investigators queried a large U.S. commercial insurance and Medicare database to assess HMT's impact on incidence of neurodegenerative diseases (NDDs; Alzheimer disease [AD], dementia, non-AD dementia, multiple sclerosis [MS], Parkinson disease [PD], and amyotrophic lateral sclerosis [ALS]) in women aged ≥45 with breast cancer diagnoses between 2007 and 2017 (mean age at diagnosis, 76.6; mean follow-up, 5.5 years; 75% white). Among almost 58,000 participants, 31% received HMT.

In analysis with propensity scor…

Reviewing Author

Andrew M. Kaunitz, MD

Disclosures

RoyaltiesUpToDate

Grant/Research SupportMerck, Mithra, Medicines360

Editorial BoardsContraception; Menopause; Contraceptive Technology Update; OBG Management; Medscape OB/GYN & Women’s Health

Andrew M. Kaunitz, MD

Disclosures

RoyaltiesUpToDate

Grant/Research SupportMerck, Mithra, Medicines360

Editorial BoardsContraception; Menopause; Contraceptive Technology Update; OBG Management; Medscape OB/GYN & Women’s Health

Does Hormone-Modulating Therapy for Breast Cancer Affect Risk for Neurodegenerative Disease?

Topics

Reviewing Author